

SEROPREVALENCE OF TOXOPLASMOSES, SYPHILIS, HEPATITIS B, HEPATITIS C, RUBELLA, CYTOMEGALOVIRUS AND HUMAN IMMUNODEFICIENCY VIRUS INFECTION AMONG PREGNANT PATIENTS FOLLOWED UP FROM 2008 TO 2012 AT HOSPITAL UNIVERSITÁRIO ANTÔNIO PEDRO, NITERÓI (RJ)

SOROPREVALÊNCIA PARA TOXOPLASMOSE, SÍFILIS, HEPATITE B, HEPATITE C, RUBÉOLA, CITOMEGALOVÍRUS E VÍRUS DA IMUNODEFICIÊNCIA HUMANA EM GESTANTES ATENDIDAS NO HOSPITAL UNIVERSITÁRIO ANTÔNIO PEDRO, NITERÓI (RJ) ENTRE 2008 E 2012

Remberto Mauricio de la Cruz Vargas Vilte¹, Kátia Martins Lopes de Azevedo², Sérgio Setúbal², Solange Artimos de Oliveira²

ABSTRACT

Introduction: Screening and treatment of infectious diseases in pregnant women have great importance in planning preventive actions and development of maternal and child health policies. **Objective:** To evaluate the seroprevalence of toxoplasmosis, syphilis, hepatitis B, hepatitis C, rubella, cytomegalovirus and human immunodeficiency virus (HIV) infection among pregnant women followed up at a University Hospital of Niterói, RJ. **Methods:** A cross-sectional study was done by reviewing serological tests recorded in the medical records of pregnant women attending the antenatal service of the Hospital Antônio Pedro, Universidade Federal Fluminense, from 2008 to 2012. **Results:** The seroprevalences found were 61.4 (IgG) and 2.4% (IgM) for toxoplasmosis; 95.1 (IgG) and 0.5% (IgM) for rubella; 95.1 (IgG) and 1.2% (IgM) for cytomegalovirus; 0.9% for hepatitis B surface antigen; 1.6% for hepatitis C virus; 1.5% for syphilis and 5.8% for HIV infection. There were no statistically significant differences between seroprevalences of patients with or without HIV infection. The rates of congenital transmission were 4.2% (2/48) for HIV, 33.3% (5/15) for toxoplasmosis, and 22.2% (2/9) for syphilis. There were congenital abnormalities in 1/5 newborn whose mother was seropositive for rubella IgG and/or IgM in the prenatal routine. Coinfection HIV/toxoplasmosis was found in one newborn. **Conclusion:** The large proportion of pregnant women susceptible to toxoplasmosis (38.8%) and hepatitis B (66.3%) shows the necessity of diagnostic and preventive measures for toxoplasmosis and HBV vaccination to reduce the risk of vertical transmission of these infections, thus improving the health of mother and newborn.

Keywords: seroepidemiologic studies; pregnant women; infectious disease transmission, vertical.

RESUMO

Introdução: A triagem e o tratamento das doenças infecciosas em gestantes são de grande importância para o planejamento de ações preventivas e a elaboração de políticas de saúde materno-infantil. **Objetivo:** Determinar a soroprevalência de toxoplasmose, sífilis, hepatite B, hepatite C, rubéola, citomegalovírus (CMV) e infecção pelo vírus da imunodeficiência humana (HIV) em gestantes acompanhadas no Hospital Universitário Antônio Pedro, Niterói (RJ). **Métodos:** Foi feito um estudo transversal por meio de revisão de testes sorológicos registrados nos prontuários médicos de gestantes atendidas, de 2008 a 2012, no Ambulatório de Pré-Natal. **Resultados:** As prevalências encontradas foram: 61,4 (IgG) e 2,4% (IgM) para toxoplasmose; 95,1 (IgG) e 0,5% (IgM) para rubéola; 95,1 (IgG) e 1,2% (IgM) para CMV; 0,9% para hepatite B (HBsAg); 1,6% para hepatite C; 1,5% para sífilis; e 5,8% para infecção pelo HIV. Não houve, entre gestantes infectadas e não infectadas pelo HIV, diferenças estatisticamente significativas nas frequências das infecções estudadas. As taxas de transmissão vertical foram de 4,2% (2/48) para o HIV; 33,3% (5/15) para toxoplasmose; e 22,2% (2/9) para sífilis. Foram detectadas alterações compatíveis com rubéola congênita em 1/5 crianças cuja mãe apresentava IgM e IgG positivas para tal infecção durante a gestação. A coinfeção HIV/toxoplasmose ocorreu em uma criança. **Conclusão:** O número de gestantes susceptíveis à toxoplasmose (38,8%) e ao vírus da hepatite B (VHB) (66,3%) revela a necessidade de medidas diagnósticas e preventivas da toxoplasmose durante a gestação e vacinação para o VHB, visando diminuir o risco dessas infecções durante a gravidez, melhorando, assim, a saúde materno-infantil.

Palavras-chave: soroprevalência; gestante; transmissão vertical.

INTRODUCTION

Toxoplasmosis, rubella, hepatitis B, hepatitis C, syphilis, cytomegalovirus, and human immunodeficiency virus (HIV) are infections that can affect pregnant women and be vertically transmitted to the

newborn. These infections are often asymptomatic among adults, and can result in severe consequences when contracted by the child during the pregnant-puerperal period, both throughout pregnancy and at the time of labor or while breast-feeding. The conduction of serological tests in the prenatal period allows the diagnosis of these infections and the adoption of measures which would enable the reduction of the harms they could cause to neonatal health¹.

In this context, it is important to monitor the susceptibility of women at reproductive age to these infections. Population serological surveys allow obtaining precise estimations of the seroprevalence, according to age group. However, these activities take a while, are

Study carried out at *Hospital Universitário Antônio Pedro (HUAP), Universidade Federal Fluminense (UFF) – Niterói (RJ), Brazil.*

¹Postgraduate Program in Medical Sciences, UFF – Niterói (RJ), Brazil.

²Discipline of Infectious and Parasitic Diseases, School of Medicine, UFF – Niterói (RJ), Brazil.

expensive, and have momentary results, considering that the proportion of seropositive people may change with the improved socio-economic and sanitary conditions, or with the adoption of national prevention and vaccination programs.

Some of the alternatives capable of providing useful approximations of population seroprevalence, for purposes of monitoring the susceptibility to these diseases include the use of serum samples collected for other population surveys, and the aliquots of serum obtained for other ends. These samples are suitable for the detection of groups of susceptible people and suggest adjustment in vaccinations. An alternative would be to use the routine tests carried out by pregnant women during the prenatal period, in order to favor an approximate awareness of the epidemiological status of the infections in the study population.

Considering the importance of knowledge on the main infectious diseases that can be transmitted from the pregnant woman to the fetus, the change in their epidemiological profile in the last years, and the lack of national publications, studies that aim at determining their prevalence are very relevant to plan for preventive actions and to elaborate on maternal and child health policies.

OBJECTIVE

This paper aimed at determining the prevalence of antibodies for toxoplasmosis, syphilis, hepatitis B and C, rubella, cytomegaloviruses, and HIV, as well as the frequency of transmission of these infections among pregnant women who were present at the Pre-Natal Outpatient ward of Hospital Universitário Antônio Pedro (HUAP), Niterói (RJ), from January 2008 to December 2012.

METHODS

This is a cross-sectional study conducted through the revision of clinical and epidemiological data and laboratory tests obtained from the medical records of pregnant women assisted from January 2008 to December 2012, in the High Risk Prenatal Outpatient Ward of HUAP. In cases of clinical and/or laboratorial suspicion of vertical transmission of the analyzed infections, a descriptive study was carried out by revising the medical records of the newborns.

Exclusion criteria

The following cases were excluded:

1. when the medical records of pregnant women and newborns were unavailable in the Medical Files of HUAP;
2. the pregnant woman did not attend the prenatal appointments, be it for abortion or changes in health service;
3. the results of the HIV serology were not in the medical records;
4. pregnancy was embryonic and/or resulted in hydatidiform mole;
5. there was no continuity in the follow-up of newborns in the medical appointments at HUAP.

Analyzed variables

The variables studied were age, schooling, city of residence, number of previous pregnancies, number of previous abortions, comorbidities and qualitative results of serological tests to detect antibodies

for toxoplasmosis, syphilis, hepatitis B and C, rubella, CMV, HIV, and detection of the hepatitis B surface antigen (HBV) (HBsAg).

Laboratory tests

Serological examinations were carried out in HUAP's laboratory, according to the recommendations of the manufacturers, and the results were classified as "positive," "negative," or "undetermined." The following tests were conducted:

1. toxoplasmosis: detection of IgM (LIASON – Toxo IgM, DiaSorin S.p.A, Italy) and IgG (LIASON – Toxo IgG, DiaSorin S.p.A, Italy);
2. rubella: detection of IgM (LIASON – Rubella IgM, DiaSorin S.p.A, Italy) and IgG (LIASON – Rubella IgG, DiaSorin S.p.A, Italy);
3. hepatitis B: detection of the surface antigen (HBsAg) (ADVIA Centaur CP Anti-HBs, Siemens Healthcare Diagnostics Inc., USA) and of antibodies for the hepatitis B surface antigen – anti-HBs (ADVIA Centaur CP Anti-HBs, Siemens Healthcare Diagnostics Inc., USA) through chemiluminescent immunoassay;
4. hepatitis C: detection of hepatitis C antibodies (anti-HCV) (ADVIA Centaur CP HCV, Siemens Healthcare Diagnostics Inc., USA);
5. syphilis: VDRL (WAMA Diagnóstica, Brazil);
6. CMV: detection of IgG (LIASON – CMV IgG II, DiaSorin S.p.A, Italy) and IgM (LIASON – CMV IgM II, DiaSorin S.p.A, Italy);
7. HIV: detection of antibodies for HIV-1/HIV-2 (ADVIA Centaur HIV 1/0/2 Enhanced Healthcare Diagnostics Inc., USA).

Statistical analysis

The data of interest were recorded, stored, and analyzed with the Statistical Package for the Social Sciences (SPSS), version 17. The categorical and continuous variables were calculated by frequencies, means, and medians. The difference between the proportions of categorical variables was carried out with Pearson's χ^2 test, with statistical significance of 5%.

The study was approved by the Research Ethics Committee of HUAP (CEP/HUAP n. 140/2011).

RESULTS

General characteristics of the population

In the book of the First Care Prenatal Outpatient at HUAP, from January 2008 to December 2012, a total of 1,112 patients were registered. Seventy-four (6.7%) patients were excluded according to the following situations: absence of medical record (36 cases); in case of pregnant women, discontinuity in attending the prenatal appointments (24 cases); absence of the results of the serologic tests for HIV (6 cases); abortion (4 cases); hydatidiform mole (2 cases); and pseudocyesis (2 cases). Therefore, the study universe was composed of 1,038 patients with properly documented serological results.

The age of the pregnant women ranged from 13 to 46 years old (mean: 26.86 years; median: 27 years), the most common being the age group of 21–30 years old (507 cases – 48.8%), followed by

31–40 years old (279 cases – 26.9%). Two-hundred and seventeen (20.9%) patients were younger than 20, and 35 (3.4%) were older than 41 years old (**Table 1**).

As to the origin, 479 (46.1%) pregnant women came from the city of Niterói; 395 (38.1%) came from São Gonçalo; and 115 (11.1%) came from other cities in the State of Rio de Janeiro.

Regarding schooling, it was observed that 391 (37.7%) pregnant women had completed elementary school, and 293 among them (28.2%) had completed high school. For 354 patients (34.1%), it was not possible to assess this item in the analyzed records (**Table 1**).

Pregnant women were assessed according to the positive or negative results of the HIV serologic tests, and considered in each one of the two groups according to the following variables: age group, schooling, and origin. The different frequencies observed between these two groups were not significant (**Table 1**).

The mean of pregnancies was 2.4 (variation of 1 to 13), and 344 (33.1%) patients were primigravida. It was observed that 279 of 1,038 (26.9%) patients had a previous history of abortion. The mean gestational age at the time of the first prenatal appointment was 20.9 weeks: 487 (47%) were in the second trimester, 266 (25.6%) were in the first trimester, and 285 (27.4%) were in the last trimester of pregnancy.

Seroprevalence study

IgG anti-*Toxoplasma gondii* antibodies were detected in 624 (61.4%) of the 1,017 pregnant women whose results were known (**Table 2**). In 24 (2.4%) patients, IgM antibodies were detected. Susceptibility to toxoplasmosis, that is, the absence of IgG, was observed in 395 (38.8%) pregnant women. There was no statistically significant association between the frequency of IgG anti-*Toxoplasma gondii* and sociodemographic variables (data not shown). An association was observed between the older age and the values of frequencies of the antibodies against *Toxoplasma gondii*, and this result was statistically significant ($p < 0.0001$) (**Table 3**).

IgG antibodies against rubella were detected in 951 (95.1%) of the 1,000 pregnant women whose results were known. There were

IgM antibodies in five (0.5%) cases. Of the 943 pregnant women tested for IgG and IgM antibodies against CMV, 897 (95.1%) and 11 (1.2%) were positive, respectively.

Nine pregnant women carried the HBsAg antigen (prevalence of 0.9%) (**Table 2**). The positive aspect of this marker was distributed in all age groups studied, and was found only in the group of pregnant women not infected with HIV. The anti-HBs antibodies were present in 296 (33.7%) of the 879 pregnant women tested. The frequency of these antibodies reduced with age, and this association was statistically significant ($p < 0.0001$) (**Table 4**). Fifteen patients were anti-HCV positive, which represents prevalence of 1.6%. Out of these 15 HCV-positive pregnant women, 2 belonged to the HIV-positive group.

Regarding syphilis, 15 (1.4%) of the 1,034 blood samples tested by VDRL were positive, but in none of the cases the FTA-ABS test was carried out to confirm the infection.

HIV was positive in 58 (5.6%) pregnant women. Among these, two (3.4%) presented the HIV/HCV coinfection, and two others (3.4%), the HIV/syphilis coinfection. One pregnant woman (1.7%) had the HIV/toxoplasmosis/rubella/herpes/HPV coinfection. Eight (13.8%) were primigravida. Of the total, 37 (63.8%) pregnant women had prior knowledge of their condition of being infected with HIV, and 21 (36.2%) among them were diagnosed with it because of the prenatal routine. Of the 58 HIV-positive pregnant women, 10 (17.2%) had already acquired immune deficiency syndrome (AIDS), and 48 (82.8%) were asymptomatic. The use of antiretroviral therapy (ART) was observed in 56 (96.6%) pregnant women, and the therapeutic scheme zidovudine, lamivudine, lopinavir, and ritonavir (AZT/3TC/LPVr) was used for most patients (39 cases – 67.2%).

Even though there were differences in the seroprevalence analyzed in HIV-positive and HIV-negative pregnant women, these changes were not statistically significant (**Table 2**).

Comorbidities

Comorbidities most commonly presented by the 1,038 pregnant women analyzed were: arterial hypertension (187

Table 1 – Sociodemographic characteristics of the population according to the result of the serological test for the human immunodeficiency virus

| Characteristics | HIV | | | P-value |
|----------------------------------|----------------------|-----------------------|----------------------|---------|
| | Positive n=58 (%) | Negative n=980 (%) | Total n=1,038 (%) | |
| Age group (in years) | | | | |
| <20 | 11 (19.0) | 206 (21) | 217 (21) | 0.3662 |
| 21–30 | 33 (56.9) | 474 (48.4) | 507 (48.8) | |
| 31–40 | 14 (24.1) | 265 (27.0) | 279 (26.9) | |
| ≥41 | 0 (0) | 35 (3.6) | 35 (3.3) | |
| Schooling | | | | |
| Elementary school | 31 (53.4) | 360 (36.7) | 391 (37.7) | 0.0921 |
| High school and higher education | 13 (22.4) | 280 (28.6) | 293 (28.2) | |
| Not informed | 14 (24.1) | 340 (34.7) | 354 (34.1) | |
| Origin | | | | |
| Niterói | 23 (39.7) | 456 (46.5) | 479 (46.1) | 0.1129 |
| São Gonçalo | 30 (51.7) | 365 (37.2) | 395 (38.1) | |
| Others | 4 (6.9) | 111 (11.3) | 115 (11.1) | |
| Not informed | 1 (1.7) | 48 (4.9) | 49 (4.7) | |

HIV: human immunodeficiency virus.

cases – 18%), obstetric and gynecologic as well as fetal changes (151 cases – 14.5%), type II and/or gestational diabetes (126 cases – 12.1%), obesity (50 cases – 4.8%), and thyroid dysfunction (29 cases – 2.8%).

Vertical transmission

Of the 24 children exposed to toxoplasmosis during pregnancy, 15 were followed-up at HUAP. In 10 children, the infection was ruled out due to the quantitative reduction in IgG values and the absence of IgM antibodies in serial serological examinations carried out after birth. Congenital toxoplasmosis was confirmed in five children, and one of them was coinfecting with HIV. One child died a few hours after labor due to severe brain, cardiac, and hepatic changes, and the other four were treated with sulfadiazine, pyrimethamine, and folic acid. Among these children, the one infected with HIV was simultaneously treated with zidovudine, lamivudine, and nevirapine. It was not possible to establish the outcome in nine children due to the lack of data in medical records (Table 5).

Out of the five newborns exposed to rubella, the infection was ruled out for two of them as their serological tests for IgG and IgM antibodies against rubella were negative. During the follow-up in the Neuropediatric Service of HUAP, there was one case of macrocephaly and retardation in psychomotor development. Even though the serologic tests had been negative for IgM

Table 3 – Frequency of the studied infections (rubella, cytomegalovirus, toxoplasmosis, syphilis) according to the result and the age group of the pregnant women.

| Age group | ^a anti-rubella IgG+ | anti-rubella IgG- | P-value |
|-----------|------------------------------------|----------------------|----------|
| <20 | 155 (93.4%) | 11 (6.6%) | |
| 20–29 | 471 (95.2%) | 24 (4.8%) | |
| 30–39 | 278 (95.5%) | 13 (4.5%) | 0.573* |
| ≥40 | 47 (97.9%) | 1 (2.1%) | |
| | ^b anti-CMV IgG+ | anti-CMV IgG- | |
| <20 | 148 (96.7%) | 5 (3.3%) | |
| 20–29 | 445 (94.7%) | 25 (5.3%) | |
| 30–39 | 262 (94.6%) | 15 (5.4%) | 0.609* |
| ≥40 | 42 (97.7%) | 1 (2.3%) | |
| | ^c anti-toxoplasma IgG + | anti-toxoplasma IgG- | |
| <20 | 90 (53.6%) | 78 (46.4%)* | |
| 20–29 | 294 (55.9%) | 213 (46.6%) | |
| 30–39 | 205 (69.7%) | 89 (30.3%) | <0.0001* |
| ≥40 | 35 (72.9%) | 13 (27.1%) | |
| | ^d VDRL+ | VDRL- | |
| >20 | 6 (3.5%) | 164 (96.5%) | |
| 20–29 | 8 (1.5%) | 507 (98.5%) | |
| 30–39 | 1 (0.3%) | 299 (99.7%) | 0.0455** |
| ≥40 | 0 (0.0) | 49 (100%) | |

*Pearson χ^2 ; **Fisher test; CMV: cytomegalovirus; ^ain 38 cases the result of anti-rubella IgG was ignored; ^bin 95 cases the result of anti-CMV IgG was ignored; ^cin 21 cases the result of anti-toxoplasma IgG was ignored; ^din 4 cases the result of VDRL was ignored.

Table 2 – Frequency of the infections studied as per the results of the serologic tests for the human immunodeficiency virus.

| Serology | HIV | | | P-value |
|------------------------|----------------------|-----------------------|----------------------|----------|
| | Positive n=58 (%) | Negative n=980 (%) | Total n=1,038 (%) | |
| Toxoplasmosis (IgG) | | | | |
| Positive | 34 (58.6) | 590 (60.2) | 624 (60.1) | |
| Negative | 22 (37.9) | 371 (37.9) | 393 (37.9) | 0.9684* |
| Not informed | 2 (3.5) | 19 (1.9) | 21 (2) | |
| Rubella (IgG) | | | | |
| Positive | 49 (84.5) | 902 (92.0) | 951 (91.6) | |
| Negative | 5 (8.6) | 44 (4.5) | 49 (4.7) | 0.1184** |
| Not informed | 4 (6.9) | 34 (3.5) | 38 (3.7) | |
| CMV (IgG) | | | | |
| Positive | 48 (82.8) | 849 (86.6) | 897 (86.4) | |
| Negative | 2 (3.4) | 44 (4.5) | 46 (4.4) | 0.5538** |
| Not informed | 8 (13.8) | 87 (8.9) | 95 (9.2) | |
| Syphilis (VDRL) | | | | |
| Positive | 2 (3.4) | 13 (1.3) | 15 (1.4) | |
| Negative | 55 (94.9) | 964 (98.4) | 1.019 (98.2) | 0.1983** |
| Not informed | 1 (1.7) | 3 (0.3) | 4 (0.4) | |
| Hepatitis B (HBsAg) | | | | |
| Positive | 0 (0.0) | 9 (0.9) | 9 (0.9) | |
| Negative | 57 (98.3) | 938 (95.7) | 995 (95.9) | 0.5896** |
| Not informed | 1 (1.7) | 33 (3.4) | 34 (3.2) | |
| Anti-HBs | | | | |
| Positive | 24 (41.4) | 272 (27.8) | 296 (28.5) | |
| Negative | 30 (51.7) | 553 (56.4) | 583 (56.2) | 0.1141* |
| Not informed | 4 (6.9) | 155 (15.8) | 159 (15.3) | |
| Hepatitis C (anti-HCV) | | | | |
| Positive | 2 (3.4) | 13 (1.3) | 15 (1.4) | |
| Negative | 53 (91.4) | 854 (87.7) | 907 (87.4) | 0.2237** |
| Not informed | 3 (5.2) | 113 (11.5) | 116 (11.2) | |

*Pearson χ^2 ; **Fisher test; HIV: human immunodeficiency virus; CMV: cytomegalovirus; HCV: hepatitis C virus.

antibodies and positive for IgG antibodies against rubella, this child was confirmed as a case of congenital rubella syndrome by the clinical-epidemiological criterion. In two cases, it was not possible to evaluate the follow-up of children because of the lack of data in medical records (**Table 5**).

In 6 out of the 11 children exposed to CMV, congenital infection was ruled out during clinical and laboratory follow-up. In the five others, it was not possible to rule out the infection due to the lack of data in medical records (**Table 5**).

Of the 15 (1.5%) newborns exposed to syphilis, congenital infection was registered in two newborns, who were then treated with crystalline penicillin. The infection was ruled out in seven newborns after clinical and laboratory follow-up (long bone x-ray, transfontanelar ultrasound, funduscopy, VDRL, and analysis of liquor). In six children, it was not possible to assess the occurrence of vertical transmission due to the lack of data in medical records (**Table 5**).

Of the nine children exposed to HBV, seven were vaccinated against hepatitis B and received anti-hepatitis B immunoglobulin in the first 12 hours of life. However, it was not possible to rule out infection in the nine newborns due to the lack of data in medical records (**Table 5**).

Table 4 – Frequency of infections caused by the viruses of hepatitis B and C according to the age group of the pregnant women.

| Age group | ^a anti-HBs IgG+ | anti-HBs IgG- | P-value |
|-----------|----------------------------|---------------|----------|
| <20 | 75 (54.0%) | 64 (46.0%) | <0.0001* |
| 20–29 | 172 (38.6%) | 273 (61.4%) | |
| 30–39 | 45 (17.8%) | 208 (82.2%) | |
| ≥40 | 4 (9.5%) | 38 (90.5%) | |
| | ^b HBsAg+ | HBsAg- | |
| <20 | 1 (0.6%) | 165 (99.4%) | 0.0538** |
| 20–29 | 2 (0.4%) | 498 (99.6%) | |
| 30–39 | 4 (1.4%) | 287 (98.6%) | |
| ≥40 | 2 (4.4%) | 45 (95.7%) | |
| | ^c anti-HCV IgG+ | anti-HCV IgG- | |
| >20 | 0 (0.0%) | 151 (100%) | 0.1638** |
| 20–29 | 7 (1.5%) | 453 (98.5%) | |
| 30–39 | 7 (2.6%) | 259 (97.4%) | |
| ≥40 | 1 (2.2%) | 44 (97.8%) | |

*Pearson χ^2 ; **Fisher test; HCV: hepatitis C virus; ^ain 159 cases, the result of anti-Hbs IgG was ignored; ^bin 34 cases, the result of HBsAg was ignored; ^cin 21 cases the result of anti-HCV IgG was ignored.

It was not possible to assess the occurrence of infection in the 15 children born from anti-HCV positive mothers due to the lack of data in medical records.

Forty-nine children, born from the 58 HIV-positive pregnant women, were followed-up at the Pediatric Infectology Service of HUAP. For 46 of them, HIV infection was ruled out with anti-HIV serological tests and viral load quantification. At the end of this study, one child was still being followed-up to complete the laboratory examinations. HIV vertical transmission was observed in two children, and one of them also had congenital toxoplasmosis. Because of the lack of medical records, it was not possible to establish the outcome for nine children followed-up at another service (**Table 5**).

DISCUSSION

The results of our study demonstrate that even though there national programs addressed to controlling these diseases (including sexually transmitted diseases – STDs), women at fertile age are still prone to the infections analyzed here, with the risk of transmitting them to their children, leading to fetal loss, congenital malformations, and neonatal death. National and international studies have been showing the importance of the early screening of infectious, vertically transmitted diseases during the prenatal period, enabling treatment, and the introduction of preventive measures to control congenital infections¹.

The seroprevalence of IgG anti-toxoplasma antibodies in our study was 61.4%. The values described for pregnant women in national studies ranged from 31%, in Caxias do Sul (RS)², to higher percentages, like 74.4%, in Recife (PE)³, and 91% in Mato Grosso do Sul¹. According to Detanico et al.², seroprevalence is higher among pregnant women aged more than 30 years old, and when there is handling of raw meats, consumption of raw vegetables or meat, raw unpasteurized milk, direct contact with the ground⁴, contact with cats and/or dogs, low socioeconomic and schooling levels, and little knowledge about the disease⁵.

In international studies, seroprevalence values of IgG anti-toxoplasma antibodies among pregnant women are also variable: 18.8% in Spain⁶, 50.6% in Morocco⁷, and 80.3% in Congo⁸. The factors associated with higher prevalence are similar to those described by national authors.

In our study, IgM antibodies were detected in 2.4% (24) of pregnant women, suggesting current or recent infection caused by this protozoan, with possibility of transmission to the fetuses. Vertical transmission took place in 5 (33.3%) of the 15 followed-up

Table 5 – Outcome of children exposed to toxoplasmosis, rubella, hepatitis B, hepatitis C, syphilis, cytomegalovirus and human immunodeficiency virus.

| Infection | Children exposed | Infection ruled out | Vertical transmission | Ignored |
|---------------|------------------|---------------------|-----------------------|------------|
| Toxoplasmosis | 24 | 10 (41.7%) | 5 (20.8%) | 9 (37.5%) |
| Rubella | 5 | 2 (40%) | 1 (20%)* | 2 (40%) |
| Hepatitis B | 9 | ** | – | 9 (100%) |
| Hepatitis C | 15 | – | – | 15 (100%) |
| Syphilis | 15 | 7 (46.7%) | 2 (13.3%) | 6 (40%) |
| CMV | 11 | 6 (54.5%) | – | 5 (45.5%) |
| HIV | 58 | 46 (79.3%) | 2 (3.4%) | 10 (17.3%) |

*Clinical diagnosis; **prophylaxis in 7 children; HIV: human immunodeficiency virus; CMV: cytomegalovirus.

cases, confirming the possibility of transmission to the fetus when the infection occurs during the gestational period, and this event may have severe consequences. In the national papers, the positive result for IgM anti-toxoplasma antibodies ranged from 0.4 to 3.4%^{9,10}.

Our results demonstrated there is still a large proportion (38.8%) of pregnant women prone to toxoplasmosis (negative IgG), who are, therefore, exposed to the risk of a prime infection during the gestational period, which indicates the need to implement measures to prevent and control toxoplasmosis during pregnancy.

The seroprevalence of IgG antibodies against rubella among the pregnant women assessed in this study was 95.1%. This result is higher to the percentages found in other national analyses: 89% in Paraná¹¹, 93.1% in São José do Rio Preto (SP)¹⁰, and 92.5% in Niterói (RJ)¹². The high values for seroprevalence may be associated with the implantation of the National Plan for the Control of Rubella and Congenital Rubella Syndrome in Brazil, in 1998¹³, which contemplates, among other strategies, the vaccination of women at a fertile age. The maintenance of high rates of immunization coverage is essential to control the congenital rubella syndrome. Even if not expected, the congenital rubella syndrome may occur in locations with low rates of susceptibility, as demonstrated by Désinor et al.¹⁴ in a region of Haiti, where only 4% of the pregnant women were susceptible.

Seroprevalence for CMV observed in our study was 95.1%, higher to the value (76.6%) found by Inagaki et al.⁹ among pregnant women in Sergipe, and lower to that (97.5%) found by Spano et al.¹⁵ in Vitória (ES). In the state of Mato Grosso do Sul, Figueiró-Filho et al.¹ detected the seroprevalence of 82%, is lower to that observed in this study. However, unlike what we observed here, chronic infection by CMV was statistically associated with older age among pregnant women.

Even though some studies have demonstrated lower percentages of seroprevalence for CMV in pregnant women than those we found – 46.8% in France¹⁶ and 68.3% in Italy¹⁷ – similar or higher values were found in the international literature in general: 92.6% in Havana, Cuba¹⁸; 87.3% in Nagasaki, Japan¹⁹; and 95% in Santiago, Chile²⁰. According to Yamamoto et al.²⁰, the high seroprevalence for CMV suggests that maternal reinfection would be the main form of congenital infection, which would lead to the search of the virus directly in the fetuses or in the newborns, using detection in the blood, urine, and saliva through viral culture or polymerase chain reaction.

The seropositivity for syphilis detected in our study was 1.4%, similar to that found in a study conducted with pregnant women in Paraná: 1.6%¹¹. The difference is that, in this study, it was possible to observe a statistically significant association between the increasing seroprevalence and the age of the women. Other studies with pregnant women, conducted in South America, also showed similar frequencies: 4.5% in Cochabamba, Bolivia²¹ and 0.6% in Lima, Peru²². In both studies, the frequency of syphilis was significantly higher among pregnant women with previous history of STD.

Unlike the observations in this study, an analysis carried out in Malawi, Zambia, and Tanzania²³ showed 6.6% seroprevalence of syphilis. Potter et al.²³ observed that the positivity for syphilis was higher among HIV-positive pregnant women (7.3%) than among HIV-negative pregnant women (2.5%). In the study by Potter et al.²³,

seven independent and statistically significant factors were correlated with the prevalence of syphilis and HIV:

1. different cities in the studied countries;
2. HIV infection;
3. age between 20 and 24 years old;
4. being a widow, separated or divorced;
5. having been treated for genital ulcer in the past year;
6. history of stillbirth;
7. history of preterm birth.

In our study, HBsAg was detected in 0.9% of the cases, which is within the positive range (0.3–1.8%) found in national studies conducted with pregnant women^{1,10,11,24-26}. Values that are similar to those observed in Brazil are also described in the global literature: 0.2% in Cordoba, Argentina²⁷; 0.6% in Granada, Spain²⁸; 0.9% in India²⁹; and 1.5% in Tripoli, Libya⁷. Studies carried out with pregnant women from African countries and China detected higher frequencies, like 8.2% in Nigeria³⁰ and 6.7% in Jiangsu, east of China³¹. The differences found are related mainly to the regional differences and to the age when the infection occurred³².

Considering the high risk of HBV vertical transmission, prophylaxis with vaccine and hyperimmune immunoglobulin in the first 12 hours of life was performed in seven of the nine children exposed in this study. However, it was not possible to rule out the occurrence of vertical transmission, since newborns were not properly followed-up after birth. Results that are similar to ours were described by Perim et al.³³ in a study about the prevalence of HbsAg conducted with pregnant women from Ribeirão Preto (SP): out of the 26 newborns of women who were HBsAg positive, only in 18 prophylaxis for hepatitis B was conducted properly.

An unexpected finding of this study was the lower frequency of anti-HB antibodies in older age groups. These antibodies were present in 296 (33.7%) of the 879 pregnant women tested. The frequency of these antibodies decreased with age, and this association was statistically significant ($p < 0.0001$). It is possible that this prevalence among pregnant women aged less than 30 years old is related to the immunization program against hepatitis B instituted by the government.

The frequency of antibodies against the hepatitis C virus (anti-HCV) in our study was 1.6% higher than the values found in other national studies carried out with pregnant women, as follows: 0.3 in Mato Grosso do Sul²⁵, 0.6% in Espírito Santo²⁶, and 0.7% in São Paulo¹⁰. Higher frequencies of anti-HCV in pregnant women are described in the international literature: 2.1% in Gabon, Central Africa³⁴, and 15.8% in Egypt³⁵. These frequencies reflect the higher HCV seroprevalence in the general population of these countries.

HCV transmission from mother to child is not a common incidence. The estimations of the percentage of vertical transmission range from 3 to 10%³⁶. In large studies, the risk seems do not exceed 4%^{37,38}. Some of the risk factors would be HIV coinfection, high maternal viral load, previous or current intravenous use of illicit drugs, vaginal labor, breastfeeding, and the female gender of the child³⁷. Many of these risk factors were never confirmed. The risk of transmission is maximum in mothers coinfecting with HIV³⁶. The high viral load at the

time of birth is also a risk factor, especially when the virus is associated with mononuclear cells in peripheral blood. Female infants have twice as much the chance of acquiring the infection from their mothers, when compared to male infants³⁷. The time when the transmission occurs is uncertain, but evidence points to intrauterine transmission³⁹. HCV is present in maternal milk, but the incidence of infection among the infants who are breast-fed is similar to those who are bottle-fed^{36,38}. However, a recent systematic study was incapable of identifying any measure (types of childbirth, type of feeding) capable of reducing the transmission from mother to child³⁶.

Even though this study has observed higher frequency of anti-HCV in HIV-positive pregnant women (3.4%), in comparison that observed among non-infected pregnant women (1.3%), this result was not statistically significant. Higher frequencies in HIV-positive pregnant women were also observed by other authors. Jamieson et al.⁴⁰, in Bangkok, Thailand, observed that the frequency of HCV was 3.8% in pregnant women infected by HIV, and 0.3% in HIV-negative pregnant women. The risk factors identified for the HCV infection were use of injectable drugs, a partner with a history of use of injectable drugs and a previous history of blood transfusion.

The frequency of seropositivity for HIV in our study was 5.8%, 14 times higher than the national estimated value (0.4%)⁴¹. However, one must consider the fact that HUAP is a reference center for the prenatal follow-up of prenatal women infected with HIV; for this reason, there is a concentration of a large number of pregnant women referred from other health units, in this hospital. In a study with similar characteristics, Gonçalves et al.¹⁰ found seroprevalence of 2.1% for HIV in 574 pregnant women who were present at the High Risk Pregnancy Unit from the Base Hospital of São José do Rio Preto (SP), from January 2006 to December 2007.

Other national studies have reported different prevalence rates among pregnant women, depending on the location and the characteristics of the study population. In the Metropolitan Region of Vitória (ES), Lima et al.²⁶ assessed 332 parturients and 202 pregnant women from February to October 1999, and obtained prevalence rates of HIV infection in both groups, and in total the percentage of women (534) was 0.9, 0 and 0.6%, respectively. The risk factors associated with HIV infection were the report of STD and the fact of having a partner with history of blood transfusion, drug usage, or seropositive for HIV. In another study, also conducted in Vitória, from January to December 1999, Miranda et al.²⁴ found prevalence of 0.8% for HIV among the 1,068 pregnant women studied. The associated risk factors were a previous history of STD, negligence regarding the use of condoms, prostitution, blood transfusions, and use of injectable drugs. One case of coinfection by HIV and HBV was identified in one of the women, by HIV and syphilis, in another one, and HBV and syphilis, in five of them²⁴.

A study about the estimated prevalence of HIV, conducted by the spatial analysis of pregnant women in Porto Alegre (RS), assessed all of the live births registered in the data base of the National System of Live Births (SINASC), and all of the newborns exposed to HIV during pregnancy registered in the data base of the National System

of Disease Notification (SINAN) in 2003. These were geo-referenced data, and the estimations of HIV seroprevalence obtained among pregnant women ranged from 0 to 8%. The areas with high prevalence of HIV-positive pregnant women were those close to slums, where the income and the schooling is lower, but fertility rates are high⁴².

Considering the specificity of our study, the HIV seroprevalence observed here is also high, when compared to values observed in other countries, as follows: 0.5% of seroprevalence for HIV among pregnant women in Lima, Peru²² and 0.54% in Cordoba, Argentina²⁷. Other studies presented even lower frequencies, like 0%, in Spain, in a study conducted by Ramos et al.⁴³. Also in Spain, seroprevalence rates of 0.15 and 0.16% were described by Gutierrez-Zufiaurre et al.⁶ and Sampetro et al.²⁸, respectively.

This study had the limitations of any retrospective analysis, especially regarding the identification of vertical transmission. A study involving the revision of medical records may be affected by the difficulty to locate the records, the quality of medical records, the possible loss of test results, and especially by the lack of response from those in charge of the children at the health service, thereby confirming or ruling out the vertical transmission of the infections assessed.

However, our study was capable of detecting important rates of vertical transmission of HIV, toxoplasmosis, and syphilis. One child presented changes compatible with congenital rubella, and five presented congenital toxoplasmosis; one of these had congenital coinfection with HIV and toxoplasma. The large number of pregnant women prone to toxoplasmosis reinforces the need for diagnostic and preventive measures against this infection during pregnancy.

Therefore, the results of this study demonstrate the importance of early prenatal serological screening for the described infections, with the goal of reducing the incidence of congenital transmission. Besides, it is important to increase the publication of information about how to prevent these infections and the necessary hygiene habits, as well as to encourage and improve the immunization coverage against rubella and hepatitis B, aiming to reduce the risk of these infections during pregnancy, thus contributing toward a better mother-child health.

Conflict of interest

The authors declare there is no conflict of interest.

ACKNOWLEDGMENTS

To the employees of the Medical File Service at Hospital Universitário Antônio Pedro.

REFERENCES

1. Figueró-Filho EA, Senefonte FRA, Lopes AHA, Morais OO, Souza Júnior VG, Maia TL, et al. Frequência das infecções pelo HIV-1, rubéola, sífilis, toxoplasmose, citomegalovirus, herpes simples, hepatite B, hepatite C, doença de Chagas e HTLV I/II em gestantes, do Estado de Mato Grosso do Sul. *Rev Soc Bras Med Trop.* 2007;40(2):181-7.

2. Detanico L, Basso RMC. Toxoplasmose: perfil sorológico de mulheres em idade fértil e gestantes. *Rev Bras Anal Clin.* 2006;38(1):15-8.
3. Porto AMF, Amorim MMR, Coelho ICN, Santos LC. Perfil sorológico para toxoplasmose em gestantes atendidas em maternidade. *Rev Assoc Med Bras.* 2008;54(3):242-8.
4. Cademartori BG, Farias NAR, Brod CS. Soroprevalência e fatores de risco à infecção por *Toxoplasma gondii* em gestantes de Pelotas, sul do Brasil. *Rev Panam Infectol.* 2008;10(4):30-5.
5. Barbosa IR, de Carvalho Xavier Holanda CM, de Andrade-Neto VF. Toxoplasmosis screening and risk factors amongst pregnant females in Natal, northeastern Brazil. *Trans R Soc Trop Med Hyg.* 2009;103(4):377-82.
6. Gutierrez-Zufiaurre N, Sanchez-Hernández J, Muñoz S, Marín R, Delgado N, Saenz MC, et al. Soroprevalencia de anticuerpos frente a *Treponema pallidum*, *Toxoplasma gondii*, virus de la rubéola, virus de la hepatitis B y C Y VIH en mujeres gestantes. *Enferm Infect Microbiol Clin.* 2004;22(9):512-6.
7. El-Magrahe H, Furarrah AR, El-Figih K, El-Ushfany S, Ghenghesh K. Maternal and neonatal seroprevalence of Hepatitis B surface antigen (HBsAg) in Tripoli, Libya. *J Infect Dev Ctries.* 2010;4(3):168-70.
8. Doudou Y, Renaud P, Coralie L, Jacqueline F, Hypolite S, Hypolite M, et al. Toxoplasmosis among pregnant women: high seroprevalence and risk factors in Kinshasa, Democratic Republic of Congo. *Asian Pac J Trop Biomed.* 2014;4(1):69-74.
9. Inagaki ADM, Oliveira LAR, Oliveira MFB, Santos RCS, Araújo RM, Alves JAB, et al. Soroprevalência de anticorpos para toxoplasmose, rubéola, citomegalovírus, sífilis e HIV em gestantes sergipanas. *Rev Soc Bras Med Trop.* 2009;42(5):532-6.
10. Gonçalves MPS, Matos CCB, Spegiorn LCJF, Oliani DCMV, Mattos LC. Seropositivity rates for toxoplasmosis, rubella, syphilis, cytomegalovirus, hepatitis and HIV among pregnant women receiving care at a Public Health Service, São Paulo State, Brazil. *Braz J Infect Dis.* 2010;14(6):601-5.
11. Reiche EMV, Morimoto HK, Farias GN, Hisatsugu KR, Geller L, Gomes ACLF, et al. Prevalência de tripanossomíase americana, sífilis, toxoplasmose, rubéola, hepatite B, hepatite C e da infecção pelo vírus da imunodeficiência humana, avaliada por intermédio de testes sorológicos, em gestantes atendidas no período de 1996 a 1998 no Hospital Universitário Regional Norte do Paraná (Universidade Estadual de Londrina, Paraná, Brasil). *Rev Soc Bras Med Trop.* 2000;33(6):519-27.
12. Oliveira SA, Camacho LA, Uzeda MCB, Velarde LGC, Siqueira MM. Serologic status of women in an urban population in Brazil before and after rubella immunization campaign using routine screening data. *J Infect Dis.* 2011;204 Suppl 2:S664-8.
13. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Manual de Vigilância epidemiológica das Doenças Exantemáticas. Brasília: Ministério da Saúde; 2003. 132 p.
14. Désinor OY, Ansèlme RJ, Laender F, Saint-Louis C, Bien-Aimé JE. Seroprevalence of antibodies against rubella virus in pregnant women in Haiti. *Rev Panam Salud Publica.* 2004;15(3):147-50.
15. Spano LC, Gatti J, Nascimento JP, Leite JPG. Prevalence of human cytomegalovirus infection in pregnant and non-pregnant women. *J Infect.* 2004;48(3):213-20.
16. Picone O, Vaulop-Fellous C, Cordier AG, Parent Du Châtelet I, Senat MV, Frydman R, et al. A 2-year study on cytomegalovirus infection during pregnancy in a French hospital. *BJOG.* 2009;116(6):818-23.
17. De-Pashale M, Agrapi C, Manco MT, Paganini A, Clerici P. Incidence and Risk of Cytomegalovirus Infection during Pregnancy in an Urban Area of Northern Italy. *Infect Dis Obstet Gynecol.* 2009; 2009: [5 p.]. doi: 10.1155/2009/206505.
18. Correa CB, Kourí V, Verdasquera D, Martínez PA, Alvarez A, Alemán Y, et al. HCMV seroprevalence and associated risk factors in pregnant women, Havana City, 2007 to 2008. *Prenat Diagn.* 2010;30(9):888-92.
19. Tagawa M, Minematsu T, Masuzaki H, Ishimaru T, Moriuchi H. Seroepidemiological survey of cytomegalovirus infection among pregnant women in Nagasaki, Japan. *Pediatr Int.* 2010;52(3):459-62.
20. Yamamoto MC, Prado PD, Wilhelm JB, Bradford R, Lira FP, Insunza AF, et al. Alta prevalencia de IgG anti cytomegalovirus em 583 embarazos: Hospital Padre Hurtado. *Rev Chil Obstet Ginecol.* 2009;74(2):102-6.
21. Villazon-Vargas N, Conde-Glez CJ, Juárez-Figueroa L, Uribe-Salas F. Prevalencia de sífilis materna y evaluación de una prueba diagnóstica rápida en Cochabamba, Bolivia. *Rev Méd Chile.* 2009;137(4):515-21.
22. Alarcon JO, Johnson KM, Courtois B, Rodriguez C, Sanchez J, Watts DM, et al. Determinants and prevalence of HIV infection in pregnant Peruvian women. *AIDS.* 2003;17(4):613-8.
23. Potter D, Goldenberg RL, Read JS, Wang J, Hoffman IF, Saathoff E, et al. Correlates of syphilis seroreactivity among pregnant women: the HIVNET 024 Trial in Malawi, Tanzania, and Zambia. *Sex Transm Dis.* 2006;33(10):604-9.
24. Miranda AE, Alves MC, Neto RL, Areal KR, Gerbase AC. Seroprevalence of HIV, hepatitis B virus, and syphilis in women at their first visit to public antenatal clinics in Vitória, Brazil. *Sex Transm Dis.* 2001;28(12):710-3.
25. Botelho CAO, Tomaz CAB, Cunha RV, Botelho MAO, Botelho LO, Assis DM, et al. Prevalência dos agravos triados no programa de proteção à gestante do Estado de Mato Grosso do Sul de 2004 a 2007. *Rev Patol Trop.* 2008;37(4):341-53.
26. Lima LH, Viana MC. Prevalence and risk factors for HIV, syphilis, hepatitis B, hepatitis C, and HTLV-I/II infection in low-income postpartum and pregnant women in Greater Metropolitan Vitória, Espírito Santo State, Brazil. *Cad Saúde Pública.* 2009;25(3):668-76.
27. Trenchi A, Gastaldello R, Balangero M, Irizar M, Cudolá A, Gallego S. Retrospective study of the prevalence of human T-cell lymphotropic virus-type 1/2, HIV, and HBV in pregnant women in Argentina. *J Med Virol.* 2007;79:1974-8.
28. Sampedro A, Mazuelas P, Rodriguez-Granger J, Torres E, Puertas A, Navarro JM. Marcadores serológicos en gestantes inmigrantes y autóctonas en Granada. *Enferm Infecc Microbiol Clin.* 2010;28(10):694-7.
29. Dwivedi M, Misra SP, Misra V, Pandey A, Pant S, Singh R, et al. Seroprevalence of hepatitis B infection during pregnancy and risk of perinatal transmission. *Indian J Gastroenterol.* 2011;30(2):66-71.
30. Olokoba AB, Salawu FK, Danburam A, Olokoba LB, Midala JK, Badung LH, et al. Hepatitis B virus infection amongst pregnant women in North-Eastern Nigeria – a call for action. *Niger J Clin Pract.* 2011;14(1):10-3.
31. Zhang S, Li RT, Wang Y, Liu Q, Zhou YH, Hu Y. Seroprevalence of hepatitis B surface antigen among pregnant women in Jiangsu, China, 17 years after introduction of hepatitis B vaccine. *Int J Gynaecol Obstet.* 2010;109(3):194-7.
32. World Health Organization. Management of hepatitis B and HIV coinfection. Clinical protocol for the WHO European Region. Copenhagen (DK): WHO; 2011. 31 p.
33. Perim EB, Passos ADC. Hepatite B em gestantes atendidas pelo Programa de Pré-Natal da Secretaria Municipal de Saúde de Ribeirão Preto, Brasil: prevalência da infecção e cuidados prestados aos recém-nascidos. *Rev Bras Epidemiol.* 2005;8(3):272-81.
34. Ndong-Atome GR, Makuwa M, Njoum R, Branger M, Brun-Vézinet F, Mahé A, et al. Hepatitis C virus prevalence and genetic diversity among pregnant women in Gabon, central Africa. *BMC Infect Dis.* 2008;8:82.
35. Stoszek SK, Abdel-Hamil M, Narooz S, El Daly M, Saleh DA, Mikhail N, et al. Prevalence of and risk factors for hepatitis C in rural pregnant Egyptian women. *Trans. R Soc Trop Med Hyg.* 2006;100(2):102-7.
36. Cottrell EB, Chou R, Wasson N, Rahman B, Guise JM. Reducing Risk for Mother-to-Infant Transmission of Hepatitis C Virus: a Systematic Review for the U.S. Preventive Services Task Force. *Ann Intern Med.* 2013;158(2):109-13.
37. Fischler B. Hepatitis C virus infection. *Semin Fetal Neonatal Med.* 2007;12(3):168-73.
38. Ray SC, Thomas DL. Hepatitis C. In: Mandell GL, Bennett JE, Dolin R. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 7th ed. Philadelphia, PA: Churchill Livingstone; 2010. p. 2534-67.
39. Mok J, Pembrey L, Tovo PA, Newell ML, European Paediatric Hepatitis C Virus Network. When does mother to child transmission of hepatitis C virus occur?. *Arch Dis Child Fetal Neonatal Ed.* 2005;90(2):F156-60.

40. Jamieson DJ, Skunodom N, Chaowanachan T, Roongpisuthipong A, Bower WA, Chotpitayasunondh T, et al. Infection with Hepatitis C Virus among HIV-Infected Pregnant Women in Thailand. *Infect Dis Obstet Gynecol.* 2008; 2008: [7 p.]. doi: 10.1155/2008/840948.
41. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de DST, Aids e Hepatites Virais. Protocolo clínico e Diretrizes terapêuticas para manejo de Infecção pelo HIV em adultos. Brasília: Ministério da Saúde; 2013.
42. Barcellos CC, Acosta LMW, Lisboa EP, Brito MRV, Flores R. Estimativa da prevalência de HIV em gestantes por análise espacial, Porto Alegre, RS. *Rev Saúde Pública.* 2006;40(5):928-30.
43. Ramos JM, Milla A, Rodríguez JC, Gutiérrez F. Seroprevalencia frente a *Toxoplasma gondii*, virus da la rubéola, virus de la hepatitis B, VIH y sífilis en gestantes extranjeras en Elche y comarca. *Med Clin (Barc).* 2007;129(17):677-8.

Address for correspondence:

SOLANGE ARTIMOS DE OLIVEIRA

Disciplina de Doenças Infecciosas e Parasitárias, Faculdade de Medicina, Hospital Universitário Antônio Pedro
Marquês do Paraná, 303 – Centro
Niterói (RJ), Brasil

CEP: 24030-210

E-mail: artimos@vm.uff.br

Received on: 02.06.2016

Approved on: 04.07.2016